"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 4 | 17 | 21 |
| 1994 | 12 | 11 | 23 |
| 1995 | 7 | 17 | 24 |
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 7 | 11 |
| 1998 | 6 | 17 | 23 |
| 1999 | 11 | 18 | 29 |
| 2000 | 9 | 12 | 21 |
| 2001 | 15 | 21 | 36 |
| 2002 | 11 | 16 | 27 |
| 2003 | 15 | 14 | 29 |
| 2004 | 22 | 17 | 39 |
| 2005 | 25 | 18 | 43 |
| 2006 | 27 | 16 | 43 |
| 2007 | 29 | 12 | 41 |
| 2008 | 24 | 19 | 43 |
| 2009 | 32 | 19 | 51 |
| 2010 | 40 | 24 | 64 |
| 2011 | 20 | 13 | 33 |
| 2012 | 18 | 9 | 27 |
| 2013 | 19 | 8 | 27 |
| 2014 | 18 | 13 | 31 |
| 2015 | 11 | 7 | 18 |
| 2016 | 16 | 6 | 22 |
| 2017 | 28 | 11 | 39 |
| 2018 | 23 | 14 | 37 |
| 2019 | 19 | 10 | 29 |
| 2020 | 14 | 13 | 27 |
| 2021 | 10 | 17 | 27 |
| 2022 | 3 | 17 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
?1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 12; 36(12):e22629.
-
Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program. Semin Thromb Hemost. 2022 Sep; 48(6):690-699.
-
In Reply. Oncologist. 2022 10 01; 27(10):e827-e828.
-
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 09 15; 28(18):3990-4002.
-
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation. Prog Transplant. 2022 12; 32(4):363-369.
-
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
-
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ? ipilimumab. Mod Pathol. 2022 11; 35(11):1529-1539.
-
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 07 05; 27(7):e589-e596.
-
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
-
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.